<unk>  prevalence in 2019<unk>  incidence is rapidly rising, along with obesity and diabetes, and has become the most common cause of liver<unk>  in developed countries, for adults, teenagers, and children. The percentage of people with<unk>  ranges from 9 to 36.9% in different parts of the world. Approximately 20% of the United States and 25% of the Asia-Pacific populations have<unk><unk><unk>  liver. Similar prevalence can be found in Europe, although less data is available.<unk>  is the most common in the Middle East (32%) and South America (30%), while Africa has the lowest rates (13%). Compared to the 2000s,<unk> and NASH respectively increased 2-fold and 2.5-fold in the 2010s in the USA.<unk>  and NASH are more prevalent in Hispanics - which can be attributed to high rates of obesity and type 2 diabetes in Hispanic populations, intermediate in Whites, and lowest in Blacks.<unk>  was observed to be twice as prevalent in men as women. For severely obese individuals, the prevalence of<unk>  rises over 90%, and for those with diabetes, over 60%, and up to 20% for normal-weight people.<unk>  is present in 65% to 90% of people that had bariatric surgery, and up to 75% of them have NASH. Ultrasonography and proton NMR spectroscopy studies suggest about 25% of the population seems to be affected by<unk>  or NASH. Although the<unk>  is commonly associated with obesity, a significant proportion of sufferers are normal weight or lean. Lean<unk>  affects between 10 and 20% of Americans and Europeans, and approximately 25% of the Asians, although some countries have a higher incidence (e.g., India has a very high proportion of lean<unk>  and almost no obese<unk> . PNPLA3 may be relevant for the progression of<unk>  in lean people. Thus, people suffering from<unk>  deserve consideration for treatment regardless of the presence or absence of obesity. In children ages 1 to 19, the prevalence was found to be approximately 8% in the general population up to 34% in studies with data from child obesity clinics. The majority of cryptogenic cirrhosis is believed to be due to NASH.<unk>  prevalence is expected to increase steadily, from 25% in 2018 to a projected 33.5% of people with<unk>  globally in 2030, and from 20% to a projected 27% of those with<unk>  will progress to NASH.
Non-alcoholic fatty liver disease
Metabolic syndrome
Alcoholic liver disease
Alcoholic hepatitis
Fatty liver disease
Autoimmune hepatitis
Viral hepatitis
Polycystic liver disease